THERAKOS™ is a specialty brand of Mallinckrodt which focuses on the delivery of extracorporeal photopheresis (ECP) immunomodulation. THERAKOS™ has shown efficacy in patients with the skin manifestations of cutaneous T-cell lymphoma and systemic sclerosis.1 Consider immunomodulation in appropriate patients.
1 Individual results may vary by patient.
We are the pioneers of ECP immunomodulation and have been dedicated to the practice and technological advancement of ECP for over 30 years.2 Find out about what this means for you.
Designed to transform service into solutions, ECP Edge is a comprehensive range of product support services to help healthcare professionals (HCPs) deliver optimized ECP immunomodulation to patients. Find out about our full range of services and select those tailored to your needs.*
*ECP Edge coverage will vary based on service contract selected. All offerings are otherwise available on a pay-per-service basis. Additional terms and conditions apply.
Our in-house support group, comprised of customer service representatives and service engineers, will help optimize delivery of ECP treatment to your patients. From system installation and operator training to maintenance and technical support, find out about our customer service hotline that is available to you 24/7/365.
Our THERAKOS™ CELLEX™ Photopheresis System is available at treatment centres across Canada. Find out how to locate the closest treatment centre near you.
Treatment centres are independent, third-party facilities not owned or operated by, or affiliated with, Therakos Inc. or Mallinckrodt Pharmaceuticals.
Download informational brochures for both HCPs and patients or watch our clinical videos to find out more about the THERAKOS™ CELLEX™ Photopheresis System.
The THERAKOS™ CELLEX™ Photopheresis System is indicated for use in the ultraviolet-A (UVA) irradiation, in the presence of the photoactive drug 8-methoxypsoralen (8-MOP), of extracorporeally circulating leukocyte-enriched blood, in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) and systemic sclerosis (SSc).
Certain underlying medical conditions contraindicate THERAKOS Photopheresis, including:
THERAKOS Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.
Hypotension may occur during any treatment involving extracorporeal circulation. Monitor the patient closely during the entire treatment.
Transient pyretic reactions, 37.7-38.9ºC (100-102ºF), have been observed in some patients within 6-8 hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labeling recommendations may result in anemia.
Venous access carries a small risk of infection and pain.
Methoxsalen Sterile Solution is contraindicated in:
Please consult the full product monograph for methoxsalen sterile solution (if used in conjunction with the THERAKOS™ CELLEX™ Photopheresis System) and the Operator’s Manual for the CELLEX system at https://www.mallinckrodt.ca/products/therakos/, or by calling us at 1-877-566-9466.
This website is intended for use by Canadian healthcare professionals only.
If you require assistance, please reach out to marketing@therakos.ca.
You are now leaving the Mallinckrodt site and moving to an external, third-party website independently operated and not managed by Mallinckrodt Pharmaceuticals. Mallinckrodt assumes no responsibility for the site. The content provided on the third-party website is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. If you do not wish to leave this site, click CANCEL. Or click OK to continue.